✦ LIBER ✦

PCN6 FACTORS INFLUENCING PHYSICIAN RECOMMENDATION FOR IMATINIB MESYLATE IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML) PATIENTS

✍ Scribed by SS Iyer; WR Doucette

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Imatinib mesylate versus allogeneic BMT

✍ Bittencourt, H; Funke, V; Fogliatto, L; Magalhães, S; Setubal, D; Paz, A; Macedo 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 165 KB

PCN86 Cost-Utility Analysis of Nilotinib

✍ Inocencio, T.J.; Seetasith, A.; Newland, A.; Bose, P.; Holdford, D. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

Compliance with taking imatinib mesylate

✍ Toru Kiguchi; Tetsuzo Tauchi; Yoshikazu Ito; Keisuke Miyazawa; Yukihiko Kimura; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 485 KB

PCN72 Modeling the Survival Loss in Pati

✍ M. Botteman; M. Magestro; A.F. Alwan 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

Reduced-intensity allogeneic transplanta

✍ Luo, Y; Lai, X-Y; Tan, Y-M; Shi, J-M; Zhao, Y-M; Han, X-Y; Zheng, G-F; Zhu, X-L; 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 116 KB

Comprehensive therapeutic outcomes of fr

✍ Kim, Dongho; Goh, Hyun Gyung; Kim, Soo-Hyun; Choi, Soo-Young; Park, Sa-Hee; Jang 📂 Article 📅 2012 🏛 Carden Jennings Publishing 🌐 English ⚖ 600 KB